Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Crofelemer (Primary)
- Indications Diarrhoea
- Focus Therapeutic Use
- Acronyms HALT-D
- 08 Jun 2018 Planned number of patients changed from 46 to 52.
- 08 Jun 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 08 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.